Trials / Unknown
UnknownNCT04931576
No Drainage During Transoral Endoscopic Thyroidectomy Vestibular Approach(TOETVA)
The Feasibility of no Drainage During Transoral Endoscopic Thyroidectomy Via the Vestibular Approach in Treatment of Papillary Thyroid Carcinoma
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 600 (estimated)
- Sponsor
- Second Affiliated Hospital, School of Medicine, Zhejiang University · Academic / Other
- Sex
- Female
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
This study evaluates the viability and safety of no drainage tube placement during transoral endoscopic thyroidectomy vestibular approach in treatment of patients with papillary thyroid carcinoma.
Detailed description
Transoral endoscopic thyroidectomy vestibular approach (TOETVA) is widely used due to its excellent cosmetic effect without scars on the body surface. In prevention of postoperative hemorrhage, a postoperative drainage tube is routinely placed in the surgical area. However, current opinion suggest that under the circumstance of strict and effective intraoperative hemostasis, routine application of drainage tube is unnecessary in conventional open thyroidectomy(COT). The research about drainage placement decision during endoscopic thyroidectomy is scarce currently. This study evaluates the viability and safety of no drainage tube placement during TOETVA on papillary thyroid carcinoma. Patients allocated to the intervention group will implace no drainage tube during TOETVA and those allocated in control group will implace one drainage tube routinely. The incidence of postoperative complications will be evaluated. The time of postoperative hospital-stay and operation time will be evaluated as well. At the same time, blood test results like WBC and CRP will be evaluated 1 day after surgery.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | no drainage tube applied | No drainage tube implacement after TOETVA |
Timeline
- Start date
- 2021-07-01
- Primary completion
- 2023-06-01
- Completion
- 2023-10-01
- First posted
- 2021-06-18
- Last updated
- 2022-06-23
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04931576. Inclusion in this directory is not an endorsement.